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ABSTRACT Recent evidence has demonstrated that mucin 1 (MUC1) is involved in many pathological
processes that occur in the lung. MUC1 is a transmembrane protein mainly expressed by epithelial and
hematopoietic cells. It has a receptor-like structure, which can sense the external environment and activate
intracellular signal transduction pathways through its cytoplasmic domain. The extracellular domain of
MUC1 can be released to the external environment, thus acting as a decoy barrier to mucosal pathogens,
as well as serving as a serum biomarker for the diagnosis and prognosis of several respiratory diseases such
as lung cancer and interstitial lung diseases. Furthermore, bioactivated MUC1-cytoplasmic tail (CT) has
been shown to act as an anti-inflammatory molecule in several airway infections and mediates the
expression of anti-inflammatory genes in lung diseases such as chronic rhinosinusitis, chronic obstructive
pulmonary disease and severe asthma. Bioactivated MUC1-CT has also been reported to interact with
several effectors linked to cellular transformation, contributing to the progression of respiratory diseases
such as lung cancer and pulmonary fibrosis. In this review, we summarise the current knowledge of
MUC1 as a promising biomarker and drug target for lung disease.
MUC1 overview
Mucin 1 (MUC1) is a large transmembrane O-glycoprotein (approximately 200 kDa) with a rigid structure
that extends up to 200–500 nm from the cell surface of primarily epithelial and hematopoietic cells [1, 2].
As a tethered mucin, MUC1 is composed of dimers of two dissimilar subunits (α and β chains) held
together by noncovalent, sodium dodecyl sulfate-labile bonds [1]. The larger subunit (α-chain or
N-terminal subunit), which is extracellular and can be shed into the lumen, comprises a signal peptide;
25–125 tandem repeats of a 20-amino acid sequence of PTS domains (regions with high proportions of
proline, threonine and serine residues) that are heavily O-glycosylated; and the sperm protein,
enterokinase and agrin (SEA) domain. However, the smaller subunit (β-chain or C-terminal subunit)
consists of a 58-amino acid extracellular domain, a single-pass 28-amino acid transmembrane domain and
a 72-amino acid cytoplasmic tail (CT) [3], which contains 18 documented potential and putative tyrosine
or serine/threonine phosphorylation sites (figure 1) [4].
At the plasma membrane, MUC1 acts as a membrane receptor, regulating several inflammatory processes
through the phosphorylation and bioactivation of MUC1-CT. Nuclear translocation of bioactivated
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MUC1-CT has been demonstrated to mediate the expression of several anti-inflammatory genes, thus
acting as an important mediator in respiratory diseases such as chronic rhinosinusitis [5], asthma [6] and
COPD [7]. MUC1-CT has also been shown to play an anti-inflammatory role in several airway infections [8].
However, bioactivated MUC1-CT also interacts with various effectors linked to transformation [4], thus
promoting carcinogenic and fibrotic processes in the lung.
The MUC1-N-terminal subunit has been shown to increase the invasive and metastatic abilities of tumour
cells [1, 9, 10], as well as providing a releasable decoy barrier during airway infection [11]. Furthermore,
the soluble MUC1-N-terminal subunits Krebs von den Lungen-6 (KL-6) and CA15-3 have been studied as
serum biomarkers in several lung diseases [12, 13].
All these findings indicate the importance of MUC1 in the development of lung diseases and suggest that
MUC1 may be useful in the diagnosis of many lung diseases, or as a therapeutic target.
MUC1 expression in lung tissue has been evaluated by immunohistochemistry analysis in several lung
diseases [14–20]. However, depending on the anti-MUC1 antibody used, a large variability of MUC1
expression has been reported [21]. Therefore, immunohistochemistry analysis should be considered to be a
weak point when evaluating MUC1 expression and its influence on mechanisms of disease.
MUC1 structure [22], interacting proteins [23], expression [24] and participation in several carcinogenic
and inflammatory processes [4, 25], including inflammation in the respiratory tract [26], have been
previously reviewed. However, the exact role of MUC1 in most of the currently known lung diseases has
not been reviewed in detail yet. This review summarises the current state of MUC1 research in several
respiratory diseases and provides an assessment of the potential of MUC1 as a diagnosis/prognosis tool
and as a treatment target for lung disease.
MUC1 and airway inflammation and infection
MUC1 has been shown to be an important modulator of innate immunity, playing an important
anti-inflammatory role during airway infection caused by bacterial and viral pathogens [27–29]. The






























FIGURE 1 Structure of mucin 1 (MUC-1). MUC1 protein comprises an N-terminal subunit (also called KL-6)
constituted by a signal peptide, a VNTR domain composed of 25–125 repeats of 20 amino acids and the SEA
domain. MUC1-C-terminal subunit has a 58-amino acid extracellular domain, a single-pass 28-amino acid
transmembrane domain and a 72-amino acid CT. The MUC1 extracellular domain can be shed into the lumen
by auto-proteolytic cleavage in the SEA domain or by the action of metalloproteinase 14 in the region
following the SEA domain. The MUC1-C extracellular domain is glycosylated on Asn-36 and then serves as a
binding site for the profibrotic galectin 3 ligand. MUC1-CT serves as a substrate for phosphorylation (18
documented and putative tyrosine and serine/threonine potential phosphorylation sites) in response to
activation of several growth factor receptors and/or kinases. The CQC motif is necessary for MUC1-C
oligomerisation and the RRK motif is necessary for MUC1-C binding to importin β and targeting to the
nucleus. β-catenin-binding site is also localised to MUC1-CT. An AUG codon downstream to the MUC1
initiation codon has been described to initiate an ARF thereby generating a novel protein, MUC1-ARF. ABL:
tyrosine-protein kinase ABL1; ARF: alternate reading frame; CT: cytoplasmic tail; FGFR: fibroblast growth
factor receptor; Gal-3: galectin-3; GSK3β: glycogen synthase kinase 3 beta; KL-6: Krebs von den Lungen-6;
MET: tyrosine-protein kinase Met; MUC1-C: mucin 1 C-terminal; MUC1-N: mucin 1 N-terminal; PDGFR:
platelet-derived growth factor receptor; PKCδ: delta isoform of protein kinase C; SEA: sperm protein,
enterokinase and agrin; VNTR: variable number tandem repeat; ZAP70: zeta chain of T-cell receptor
associated protein kinase 70.
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which attenuates nuclear factor (NF)-κB activation and reduce tumour necrosis factor (TNF)-α and
interleukin (IL)-8 secretion [8]. Furthermore, the anti-inflammatory effect of MUC1 has been reported to
require only the MUC1 cytoplasmic domain, instead of the MUC1 entire molecule [8].
Immunoprecipitation and immunofluorescence studies revealed that MUC1-CT constitutively forms a
protein complex with TLR5 [30]. Since all TLR adaptor proteins (myeloid differentiation primary response
gene 88 (MyD88) for TLR2, 4, 5, 7, and 9 and TIR (Toll/interleukin-1 receptor)-domain-containing
adapter-inducing interferon-β (TRIF) for TLR3) share the conserved TIR domain, it has been suggested
that MUC1-CT might suppress TLR signalling by associating with the TIR domains of TLRs, acting as a
steric hindrance/decoy receptor and preventing recruitment of adaptor proteins to their respective
receptors (figure 2) [30]. Nevertheless, further research is needed to confirm that MUC1-CT forms protein
complexes with all the TLRs, and, to confirm the direct interaction between MUC1-CT and TIR domains.
As an example of bacterial airway infection, MUC1 has been reported to act as an extracellular adhesion
site for Pseudomonas aeruginosa, an opportunistic pathogen that colonises the lungs in several airway
diseases, including bronchiectasis, cystic fibrosis, and nosocomial pneumonia [31–34]. Initially, it was
suggested that during early stage infection, primary human airway epithelial cells and macrophages sense
P. aeruginosa infection via TLR5 recognition of flagellin and subsequent MyD88-dependent secretion of
TNF-α and IL-8. Following this, IL-8 recruits neutrophils that release neutrophil elastase (NE) into the
airway lumen. TNF-α and NE secretion results in increased expression of MUC1 at the apical surfaces of
lung epithelial cells. Therefore, during late-stage infection, P. aeruginosa-induced MUC1-CT tyrosine
phosphorylation leads to inhibition of TLR5 signalling, downregulation of inflammation and promotion of
neutrophil apoptosis, which is important for the removal of inflammatory cells from the lung (figure 2)
[35, 36]. By contrast, KATO et al. [37] recently suggested that stimulation of primary human bronchial
epithelial cells with P. aeruginosa or flagellin increases the release of transforming growth factor (TGF)-α,
which leads to autocrine activation of epidermal growth factor receptor (EGFR) at the cell surface.
Furthermore, P. aeruginosa stimulation of human or mouse macrophages has also been reported to
enhance TNF-α release. Therefore, TGF-α via autocrine EGFR activation as well as TNF-α via paracrine
signalling have both been reported to increase MUC1 expression in bronchial epithelial cells, thus
increasing MUC1-CT/TLR5 association and inhibiting TLR5 signalling [38]. P. aeruginosa has also been
shown to upregulate the expression of MUC1 in primary human alveolar macrophages via activation of








































































FIGURE 2 The role of MUC1 in airway infection/inflammation. During early stage of infection, primary human airway epithelial cells sense
Pseudomonas aeruginosa via TLR5 (1), Haemophilus influenzae (NTHi) via TLR2 (2), and RSV via TLR3 (3), which is expressed in endosomes. After
recognition, MyD88/TRIF-dependent secretion of TNF-α and IL-8 is produced (4). Following it, IL-8 and TNF-α lead to an increased expression of
MUC1 at the apical surface of lung epithelial cells (5). During the late-stage of infection, P. aeruginosa/NTHi/RSV-induced MUC1-CT tyrosine
phosphorylation (1) leads to MUC1-CT interaction with TLR5/TLR2/TLR3 (2), leading to TLR signalling downregulation (3) and inhibition of
inflammation (4). CT: cytoplasmic tail; ERK: extracellular signal-regulated kinase; NFκB: nuclear factor-κB; IL: interleukin; MUC1: mucin 1;
MyD88: myeloid differentiation primary response gene 88; RSV: respiratory syncytial virus; TIR: Toll/interleukin-1 receptor; TLR: Toll-like
receptor; TNF: tumour necrosis factor; TRIF: TIR (Toll/interleukin-1 receptor)-domain-containing adapter-inducing interferon-β.
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macrophages and emphasising the importance of MUC1 as a negative regulator of macrophage-generated
inflammatory responses [39].
Similarly, MUC1 has been shown to be part of a feedback loop that downregulates TLR2-induced IL-8 and
TNF-α production during late-stage airway epithelial cell infection with nontypeable Haemophilus
influenzae (figure 2) [27].
MUC1 has been shown to also exhibit anti-inflammatory effects during TLR3 activation by respiratory
syncytial virus, which is considered the leading cause of viral bronchiolitis and pneumonia, both of which
represent a major health and economic burden worldwide [40, 41]. Following viral infection, TLR3, which
is expressed in endosomes by airway epithelial cells, senses viral-derived double-stranded RNA, triggering
TRIF-dependent inflammatory and apoptosis signalling pathways that release TNF-α, which in turn
upregulate MUC1. The interaction of MUC1-CT with TLR3 supresses TNF-α release, terminating the
inflammatory response (figure 2) [28, 42].
The protective role of MUC1 during respiratory tract infections is further supported by evidence reported
from research into MUC1 and certain gastrointestinal infections. Indeed, MUC1 has demonstrated to play
a protective role during infection with gastrointestinal pathogens such as Helicobacter pylori [43, 44] and
Campylobacter jejuni [45], which also induce inflammation via TLR signalling.
Altogether, these results suggest anti-inflammatory function of MUC1 in the host inflammatory response
to microbial respiratory tract infection, specifically in the resolution phase of inflammation through its
ability to inhibit TLR signalling. Therefore, genetic or epigenetic alterations of MUC1-CT might block its
ability to inhibit inflammatory signalling, thus contributing to the progression of respiratory tract
infections, as well as, to the pathophysiology of chronic inflammatory lung diseases.
MUC1 and chronic rhinosinusitis with nasal polyps
Chronic rhinosinusitis (CRS) encompasses a group of heterogeneous disorders associated with
inflammation of the nasal and sinus mucosa with or without the presence of nasal polyps (NP). Different
inflammatory phenotypes have been described in NP: NP without asthma or aspirin intolerance (NPwA),
NP with aspirin-tolerant asthma (NP-ATA), and NP with aspirin-intolerant asthma (NP-AIA).
The proposed CRS aetiology includes both host and environmental factors that activate the host innate
and adaptive immune responses involved in pathogenesis [46, 47]. However, depending on the ethology,
CRS immune responses might be different.
Cigarette smoke (CS) has been identified as a significant risk factor for the development of CRS [48].
Cigarette smoke-associated pathological phenotype includes globet cell metaplasia (GCM) and
overproduction of mucus among others [49]. Recently, it has been reported that in response to cigarette
smoke exposure, total protein levels of MUC1 are not altered in the lung tissue [50]. However, an
expansion of basal/intermediate cells enriched with MUC1 in the intracellular compartment is apparent
following exposure to cigarette smoke, leading to GCM and MUC5AC overproduction [50].
Eosinophilic inflammation is another hallmark of chronic rhinosinusitis with nasal polyps (CRSwNP).
Staphylococcus aureus exotoxins are among the best characterised elicitors of eosinophilic inflammation
and are thought to be heavily involved in the pathogenesis of CRSwNP through their behaviour as
superantigens [51]. S. aureus has been observed to promote the production of IL-22 by NP cells. In this
context, IL-22 regulates chronic inflammation and has been shown to significantly enhance the levels of
MUC1 expression in NP cells, which are significantly and positively correlated with IL-22 receptor mRNA
levels [52].
Oral systemic corticosteroids are the first-line therapy for patients with CRSwNP [53]. Among responders,
corticosteroids have been shown to upregulate membrane-tethered mucins (MUC1 and MUC4) while
downregulating secreted mucins (MUC5AC and MUC5B) in NP [54]. No differences for MUC1
expression have been observed among responders in the NPwA, NP-ATA and NP-AIA groups [5].
However, a large number of patients show resistance to the effects of systemic corticosteroids
(CR-CRSwNP).
Dexamethasone has been shown to induce the formation of a protein complex between MUC1-CT and
glucocorticoid receptor α (GRα), which results in translocation of GRα into the nucleus to exert its
anti-inflammatory effects (figure 3) [5]. However, since patients with CR-CRSwNP exhibit significantly
lower expression of MUC1 in the NP epithelium, as well as upregulation of TLR2 and TLR5 [5], it results
in overactivation of TLR signalling and subsequent inflammation, contributing to the loss of corticosteroid
efficacy in these patients. The same pattern of MUC1 expression was also observed between patients with
CR-CRSwNP showing NPwA, NP-ATA and NP-AIA [5].
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Patients with CR-CRSwNP show significantly higher extracellular signal-regulated kinase (ERK) 1/2
phosphorylation than responders [5]. Similarly, these patients also show higher glucocorticoid receptor
(GR)-Ser226 phosphorylation [5], which has been reported to enhance GR nuclear export, thus
contributing to termination of GR-mediated transcription [55]. It suggests that GR-Ser226
hyperphosphorylation is induced by ERK1/2 hyperphosphorylation, leading to an inhibition of
corticosteroid-induced GRα nuclear translocation [56]. Therefore, MUC1 downregulation in patients with
CR-CRSwNP has been suggested to contribute to the loss of corticosteroid efficacy, by GR-Ser226
hyperphosphorylation, which is consequence of the enhanced TLR-induced ERK1/2 phosphorylation, and
by the reduced formation of the MUC1-CT-GRα transcription complex [5]. Furthermore, in the absence
of ligand, GR resides predominantly in the cytoplasm, sequestered in a multimeric chaperone complex
comprising heat shock protein (hsp) 90, hsp70, and other factors that prevent its degradation and assist in
its maturation [57]. MUC1-CT has been shown to form a complex with hsp90 [58]. Therefore, MUC1-CT
may bind the GRα-chaperone complex, leading to nuclear translocation of the mature complex (figure 3).
Overall, these findings suggest that increased or altered localisation of MUC1 expression might be a
defence mechanism to compensate for excessive inflammation in patients with CRSwNP, modulating the
anti-inflammatory effects of the corticosteroid therapy used and inhibiting overactivation of TLR-triggered
inflammation.
MUC1 and asthma
Bronchial asthma is a chronic airway inflammatory disease whose strongest risk factors are a combination
of genetic predisposition with environmental exposure to inhaled substances and particles that may
provoke allergic reactions or irritate the airways.
The symptoms of patients with mild to moderate asthma are often well controlled with low doses of
inhaled corticosteroids (ICS). However, the symptoms of most patients with severe asthma are not well



























































FIGURE 3 The role of MUC1 in the corticosteroid mediated anti-inflammatory response in CRS, severe asthma and COPD. The TLR recognition of
airway pathogens such as Pseudomonas aeruginosa or Staphylococcus aureus, as well as, cigarette smoke (1) triggers a MyD88-mediated
inflammatory response (2). Among corticosteroid responder patients, corticosteroids increase MUC1 expression. The MUC1-CT interacts with TLR,
inhibiting TLR inflammatory signalling (3). Dexamethasone (DEXA) treatment induces the formation of a protein complex between MUC1-CT and
GRα, which helps GRα to translocate into the nucleus to exert its anti-inflammatory effects (4). Corticosteroid resistance patients show lower
expression of MUC1. Therefore, it is produced an overactivation of TLR signalling (1) and subsequent inflammation (2), which leads to GR-Ser226
phosphorylation through ERK 1/2 hyper-phosphorylation (3). Therefore, MUC1-CT downregulation and GR hyperphosphorylation inhibit the
corticosteroids-induced GRα nuclear translocation and GR anti-inflammatory mediated effects (4). CRS: chronic rhinosinusitis; CT: cytoplasmic
tail; ERK: extracellular signal-regulated kinase; NFκB: nuclear factor-κB; GR: glucocorticoid receptor; GRE: glucocorticoid response element;
Hsp: heat shock protein; IL: interleukin; LPS: lipopolysaccharide; MUC1: mucin 1; MUC1-CT: MUC1 cytoplasmic domain; MyD88: myeloid
differentiation primary response gene 88; TIR: Toll/interleukin-1 receptor; TLR: Toll-like receptor; TRIF: TIR-domain-containing adapter-inducing
interferon-β.
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Four distinct asthma inflammatory phenotypes can be identified based on the presence (or absence) of
increased levels of eosinophils and neutrophils. These phenotypes are termed eosinophilic (increased
eosinophils); neutrophilic (increased neutrophils); granulocytic asthma (MGA) (increased both eosinophils
and neutrophils); and paucigranulocytic (normal levels of eosinophils and neutrophils). Up to now, any
association between MUC1 expression and the different asthma inflammatory phenotypes has not been
reported yet. However, similar to patients with CR-CRSwNP, corticosteroid resistance in patients with
uncontrolled severe asthma has been associated with MUC1 downregulation in human bronchial epithelial
cells (HBECs) and blood neutrophils, as compared with patients with mild asthma and healthy controls
[6]. Indeed, neutrophils and bronchial epithelial cells from patients with severe asthma are less sensitive to
the anti-inflammatory effects of corticosteroids [6]. Similar results have been reported in an
ovalbumin-induced inflammatory asthma model, in which wildtype (WT) mice, but not MUC1 knockout
(KO) mice, responded to the anti-inflammatory effects of corticosteroids [6].
As it was described above, corticosteroids mediate some of their anti-inflammatory effects by forming
MUC1-CT/GRα nuclear transcription complexes (figure 3) [5]. HBECs from patients with severe asthma
exhibit increased GR-Ser226 phosphorylation compared with cells from patients with mild asthma and
healthy controls. Furthermore, immunoprecipitation experiments revealed that the expression levels of
GRα/MUC1-CT complexes are decreased in HBECs from severe asthmatics [6]. In this context, in an
ovalbumin-induced inflammatory model of asthma, corticosteroids have been shown to promote bronchial
epithelial nuclear translocation of the MUC1-CT/GRα complex in WT mice, inducing the expression of
corticosteroid-inducible anti-inflammatory genes. By contrast, GRα nuclear translocation is not observed
in MUC1-KO mice [6]. Corticosteroids also inhibit inflammatory cell extravasation to lung tissue. When
pulmonary artery endothelial cells (HPAECs) are transfected with small interfering RNA targeting MUC1,
they become resistant to the effects of corticosteroids inhibiting neutrophil adhesion and downregulation
of intracellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM) and E-selectin.
These results suggest that MUC1 not only mediates corticosteroid regulation of anti-inflammatory gene
expression but also mediates the inhibitory effects of corticosteroids on neutrophil migration and adhesion
to HPAECs [6].
Viral or bacterial infections are observed in 70% of inpatients with an asthma exacerbation [60]. Therefore,
MUC1-CT downregulation in severe asthma patients may enhance viral and bacterial-induced TLR
signalling (figure 3) [30], triggering sustained inflammation in the pathogenesis of asthma [61]. However,
elevated KL-6 serum levels have been reported in acute exacerbations of paediatric patients with bronchial
asthma [62], suggesting that KL-6 may become a useful biomarker for the diagnosis and prognosis of
asthma.
The death of epithelial cells in asthmatic airways also plays a regulatory role in severe asthma [63]. Indeed,
multiple mechanisms have been implicated in mediating epithelial apoptosis in asthma, including viral
infection [64]. It has been demonstrated that asthmatic patients have an impaired antiviral response, and it
has been hypothesised that this may allow certain viruses to proliferate in epithelial cells with
consequential necrosis, the release of damage-associated molecular patterns (DAMPs), and persistent
inflammation [65, 66]. In this context, MUC1 downregulation in HBECs has been shown to impair the
antinecroptotic (necrosis regulated by orchestrated pathways) effects of glucocorticoids in these cells [67].
In summary, these findings suggest that MUC1 expression mediates the corticosteroids effects in patients
patients with severe asthma.
MUC1 and COPD
COPD is a chronic inflammatory, progressive, and debilitating lung disease mainly caused by chronic
exposure to cigarette smoke [68]. Anti-inflammatory options for COPD are based on corticosteroids.
However, similar to severe asthma [6] and CRSwNP [5], the loss of corticosteroid anti-inflammatory
efficacy is common in patients with COPD [69].
MUC1-CT has been shown to be downregulated in lung tissue, isolated bronchial epithelial cells and
sputum neutrophils from smokers and corticosteroid resistant patients with COPD defined according to
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as GOLD II (moderate disease) and
GOLD III (severe disease), without recent exacerbations [7]. Additionally, the forced expiratory volume
(FEV1%) of smokers and patients with COPD without recent exacerbations has been directly correlated
with MUC1 lung tissue expression [7].
Similar to the mechanism of action of corticosteroids in asthma [6] and CRSwNP [5], it has been
suggested that corticosteroids given to patients with COPD also partially mediate their anti-inflammatory
effects by forming MUC1-CT-GRα complexes that translocate to the nucleus to increase the expression of
anti-inflammatory genes [7]. Furthermore, TLR4, whose inflammatory downstream signalling is activated
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by cigarette smoke [70], is chronically elevated in bronchial epithelial cells and neutrophils from patients
with COPD [7, 71]. Therefore, the increased expression of TLR4 and decreased expression of MUC1-CT
could explain the greater inflammatory response in patients with COPD, as well as the lack of
corticosteroid responsiveness (figure 3). Indeed, HBECs transiently transfected with siRNA-MUC1 have
been reported to be resistant to the anti-inflammatory effects of corticosteroids in response to cigarette
smoke extract [7]. Consistent with this, corticosteroids are unable to exert anti-inflammatory effects in
lungs from a MUC1-KO model of acute cigarette smoke inflammation [7]. Nevertheless, the loss of MUC1
expression in the lungs of patients with COPD is still controversial because there is evidence of bronchial/
alveolar epithelium of patients with COPD which display highly positive areas of KL-6 staining in contrast
to the situation in nonsmokers and smokers [72]. Furthermore, as it was previously mentioned, it has been
also reported that oxidative stress upregulates MUC1 expression [73] or modifies the localisation of MUC1
expression to the intracellular compartment of hyperplastic intermediate cells [50].
MUC1 downregulation is not the only cause for the lack of corticosteroid responsiveness in COPD.
Indeed, the endogenous glucocorticoid hydrocortisone and the synthetic glucocorticoids administered to
patients with COPD function via histone deacetylase 2 (HDAC2)-regulated epigenetic modifications to
suppress pro-inflammatory gene transcription. Therefore, changes in the histone acetylation/deacetylation
balance due to oxidative stress induced by cigarette smoke may be also an important factor in inducing
glucocorticoid resistance in patients with COPD [74].
Similar to asthma, respiratory virus infections are a major cause of COPD exacerbations, sometimes
resulting in secondary bacterial infections. In this context, MUC1-CT expression in sputum has been
reported to be increased in acute phase COPD exacerbations (AECOPD) compared with sputum from the
remission phase [75], thus suggesting a protective role of MUC1 during AECOPD. Furthermore, linear
regression analysis has shown that, during COPD acute exacerbation, the increased levels of sputum
MUC1-CT fragments are positively correlated with sputum neutrophil number [75].
The extracellular domain (EC) of MUC1 has also been shown to be elevated in sputum not only from
patients with AECOPD, but also patients with GOLD I–III COPD [72, 75, 76]. The contribution of MUC1
shedding to mucous biology is not fully understood. Nevertheless, it might be hypothesised that the
untethered MUC1-N-terminal subunit may contribute to mucus hypersecretion and increased amount of
sputum in patients with COPD, likely serving as a protective barrier against invading pathogens. However,
long-term mucous plugging, particularly of the small airways, might also contribute to airflow limitation.
Therefore, elevated MUC1-EC levels in sputum can have beneficial and nonbeneficial effects in patients
with COPD.
Elevated KL-6 serum levels have been also detected in patients with COPD, although elevated levels have
also been observed in smokers regardless of COPD diagnosis [72].
In summary, these findings suggest that MUC1 expression levels in patients with COPD are dependent on
the nature of patients with COPD, with differences reported between AECOPD and patients with stable
(without recent exacerbations) COPD. It is possible that the different MUC1 subunits play different roles
in COPD, as MUC1-CT has been shown to participate in modulation of the anti-inflammatory effects of
corticosteroids in patients with stable COPD. However, the significance of the elevated levels of
MUC1-EC/KL-6 in the development and progression of COPD is still unknown.
MUC1 and lung cancer
MUC1 basal expression is generally restricted to the apical/luminal side of cells [3]. However, MUC1 has
long been viewed as a tumour-associated molecule due to its frequent overexpression and aberrant
glycosylation in many carcinomas [3], in which there is loss of polarity and aberrant cell surface
distribution [77]. In this context, several clinical studies based on immunohistochemical staining [14–19]
and meta-analysis studies [78, 79] have demonstrated a negative prognostic association of tumour MUC1
overexpression and depolarised cellular distribution in patients with nonsmall cell lung cancer (NSCLC).
Nevertheless, some contradictory findings have also been reported, although they represent minor
contributions [80–82].
Elevated levels of MUC1 have been detected more frequently in adenocarcinoma (86.3%) and other
NSCLCs (74.1%) compared with squamous cell carcinoma tissue (39.1%) [15]. However, some studies
have shown that MUC1 expression is increased during the progression of pre-malignant lung lesions to
invasive carcinoma; this increase is significant for squamous cell carcinoma but not for adenocarcinoma [83].
CA15-3 serum levels have also been reported to be significantly increased and correlated with metastasis
in patients with lung cancer [84, 85]. Otherwise, preoperative serum KL-6 levels have been identified as a
simple and novel predictor of recurrence following curative surgery in patients with NSCLC [86–88], while
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postoperative serum KL-6 levels have been identified as a prognostic factor for resected patients with
NSCLC [89]. In this context, the degree of the decrease of natural autoantibody to KL-6/MUC1 has been
correlated with impaired NSCLC prognosis [90]. By contrast, recent findings have reported no significant
difference in serum MUC1 levels between patients with NSCLC and healthy individuals, although higher
plasma exosomal MUC1 levels have been detected in patients with NSCLC [91].
In lung cancer cells, STAT3 [92] and 14-3-3ζ [93] oncogenes have been shown to regulate the expression
of MUC1 in a promoter-dependent manner. Overexpressed and depolarised MUC1 has been shown to
inhibit lung cancer cell apoptosis and to induce proliferation, the epithelial–mesenchymal transition
(EMT), tumour growth and angiogenesis and metastasis [92–95]. The MUC1-N-terminal subunit has been
shown to increase the invasive and metastatic capability of tumour cells by different mechanisms:
1) reducing cell–cell adhesion by disturbing E-cadherin interactions between adjacent cells [9]; 2) reducing
cell–extracellular matrix adhesion through inhibition of integrin-mediated cell adhesion to extracellular
matrix components [10]; and 3) interacting with adhesion molecules such as endothelial ICAM-1, which
triggers invasion of MUC1-expressing tumour cells into the endothelium and reattachment at distant sites
of metastasis (figure 4) [1].
MUC1-C-terminal subunit has been reported to interact with the β-galactosidase binding lectin galectin-3
(figure 1), increasing MUC1 association with EGFR and leading to EGFR activation and signalling, which
mediates epithelial cell growth and survival [96]. Independently of EGFR, galectin 3 binding to MUC1-C
has also been shown to promote MUC1-CT phosphorylation, activating mitogen-activated protein kinase
(MAPK) and PI3K/AKT signalling pathways, resulting in cell proliferation, motility, and tumour
angiogenesis [25, 97, 98]. Similarly, other transmembrane receptors such as platelet-derived growth factor
receptor (PDGFR)-β [99], fibroblast growth factor receptor (FGFR) 3 [58] and Met [23] and ErbB1–4
receptors [77, 100] have also been shown to phosphorylate MUC1-CT (figure 1), promoting cell































FIGURE 4 The role of MUC1 in lung cancer. (1) MUC1 is overexpressed and depolarised in lung cancer.
Therefore, MUC1 interactions with potential binding partners are increased under these circumstances, thus
increasing the invasive and metastatic capability of tumour cells by different mechanisms: (2) reducing cell–
cell adhesion through disturbing E-cadherin interactions between adjacent cells, (3) reducing cell–ECM
adhesion through inhibition of integrin-mediated cell adhesion to ECM components, and (4) interacting with
adhesion molecules such as the endothelial ICAM-1. (5) MUC1-C-terminal subunit interacts with galectin-3,
increasing MUC1 association with the EGFR and leading to EGFR activation and signalling, which mediates
epithelial cell proliferation and survival. (6) Galectin-3 binding to MUC1-C also phosphorylates MUC1-CT,
activating mitogen-activated protein kinase and PI3K/AKT signalling pathways, which lead to cell proliferation
and motility. (7) β-Catenin preferentially binds to the phosphorylated intracellular tail of MUC1, thus also
contributing to the decrease of cell–cell adhesions through E-cadherin. (8) MUC1-CT/β-catenin complex
translocates into the nucleus to regulate genes involved in cell proliferation and differentiation. (9) MUC1-N
(KL6) is shed from the cell surface and has demonstrated to be a prognostic and treatment responsiveness
serum biomarker in lung cancer. AKT: protein kinase B; ECM: extracellular matrix; EGFR: epidermal growth
factor receptor; ERK: extracellular signal-regulated kinase; ICAM: intracellular adhesion molecule; KL-6:
Krebs von den Lungen-6; LEF: lymphoid enhancer factor; MUC1: mucin 1; MUC1-CT: MUC1 cytoplasmic
domain; TCF: T-cell factor protein.
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phosphorylated intracellular tail of MUC1 (figure 1), also contributing to the decrease in cell–cell
adhesions through E-cadherin [25]. MUC1-CT/β-catenin complexes translocate to the nucleus and
regulate genes involved in cell proliferation and differentiation (figure 4) [101].
Recently, it has been shown that an AUG codon downstream to the MUC1 initiation codon initiates an
alternate reading frame (ARF) thereby generating a novel protein, MUC1-ARF (figure 1). The amino acid
sequence of the MUC1-ARF variable number tandem repeat (VNTR) as well as N- and C- sequences
flanking it differ entirely from those of MUC1-transmembrane and it has been shown that MUC1-ARF
protein mainly localises in the nucleus of malignant epithelial cells of pancreatic cancer and breast cancer.
In this context, further research would be needed to address if MUC1-ARF is also expressed in lung
cancer, as well as, to describe the link between MUC1-ARF and malignancy.
In the clinic, paclitaxel (PTX) is an important first-line chemotherapeutic agent against lung cancer [102, 103].
However, its treatment can generate resistance, which has been associated with enhanced MUC1-C
expression in NSCLC [104]. Alternatively, among agents for the treatment of lung cancer, the EGFR
tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been established as options for first-,
second-, or third-line, or maintenance, treatment. Nevertheless, EGFR activating mutations in NSCLC cells
frequently develop, resulting in resistance to EGFR-TKIs. In this context, targeting the oncogenic protein
MUC1-C has been shown to inhibit mutant EGFR-mediated signalling and survival of NSCLC cells,
suggesting a potential approach for the treatment of EGFR-TKI-resistant NSCLC [105]. Monitoring of
circulating KL-6 levels in patients with NSCLC prior to and 2 weeks after the start of EGFR-TKI treatment
revealed that serum KL-6 levels are increased in EGFR-TKI no-responder patients, which is accompanied
by disease progression and reduced survival. By contrast, in partial-response patients, KL-6 serum levels
significantly reduced after 2 weeks of EGFR-TKI treatment [106]. Furthermore, it has been suggested that
patients with NSCLC with high serum KL-6 levels [106, 107] and MUC1 mRNA positivity in blood have
unfavourable responses and poor clinical outcomes when treated with gefitinib [108]. Therefore, KL-6
serum levels and/or MUC1 mRNA blood levels may be promising noninvasive and repeatable markers for
predicting the efficacy of EGFR-TKIs, which could help in the choice of treatment for different patients.
By contrast, other findings have demonstrated that monitoring of KL-6 levels in the intrabronchial
epithelial lining fluid near the tumour before and 2 weeks after the start of gefitinib treatment can predict
tumour response at 4 weeks, whereas serum levels do not. However, the median KL-6 level near the
tumour is significantly higher in treatment responders than in nonresponders prior to treatment [109].
Importantly, aberrant overexpression of MUC1-C in NSCLC has been linked to the induction of
programmed death ligand 1 (PD-L1) [110], which promotes the evasion of NSCLC cells from immune
recognition [111]. Therefore, several vaccines using MUC1 as an antigen have been developed and
investigated as an immunomodulatory approach to the treatment and prevention of lung cancer. TG4010
(a modified vaccinia virus expressing MUC1 and IL-2) has been studied in a phase II trial in combination
with first-line chemotherapy in patients with stage IV untreated NSCLC. This trial demonstrated a small
but statistically significant improvement in progression-free survival [112]. Another vaccine, tecemotide
(L-BLP25; a liposome-based vaccine consisting of a synthetic 25-amino acid lipopeptide derived from the
tandem repeat region of MUC1, together with the nonspecific adjuvant monophosphoryl lipid A and three
different lipids [113]), has been administered in a phase III study as maintenance therapy for unresectable
stage III/IV NSCLC following treatment with platinum-based chemotherapy and radiation. Results from
this clinical trial have already shown an improved overall survival [114, 115]. Additionally, two clinical
trials are currently investigating the combination of MUC1 targeting vaccines with anti-PD1 therapy in
advanced NSCLC: one using the above mentioned TG4010 vaccine (NCT02823990), and another using
the CV301 vaccine (NCT02840994), which targets both MUC1 and carcinoembryonic antigen (CEA).
Finally, preliminary studies have reported that the MUC1-targeted dendritic cell-based vaccine also
significantly prolongs the survival of patients with MUC1-expressing lung cancer [116].
In summary, MUC1 is considered a lung cancer-associated molecule, since its overexpression and
depolarisation have been shown to be linked to lung cancer progression. Therefore, part of the clinical
efforts are currently focused on targeting MUC1 to treat lung cancer. Furthermore, numerous studies have
demonstrated that CA-15-3 and KL-6 are reliable lung cancer prognostic and treatment responsiveness
biomarkers, thus highlighting the potential use of MUC1 in the treatment of lung cancer.
MUC1 and interstitial lung disease
Elevated KL-6/MUC1 serum levels have been observed in >70% of patients with interstitial lung diseases
(ILDs) [117, 118]; serum levels are negatively correlated with the diffusing capacity of lungs for carbon
monoxide, as well as positively correlated with the high-resolution computerised tomography (HRCT)
score [119]. Additionally, serum levels of KL-6 have been reported to be significantly correlated with KL-6
levels in bronchoalveolar lavage fluid (BALF), which are significantly correlated with the numbers of
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total cells, lymphocytes, and neutrophils in BALF from patients with ILD [120] and KL-6 expression in
regenerating alveolar type II (ATII) cells from ILD tissue [117]. Therefore, KL-6 serum levels are useful for
evaluating the extent of ILDs, predicting disease outcome, monitoring the clinical course, and identifying
patients with ILDs who are at increased risk for subsequent mortality [117–119, 121]. Nevertheless, ILD is
a term that comprises the pathologies described below.
Hypersensitivity pneumonitis
Measurement of serum KL-6 concentrations is useful to screen for hypersensitivity pneumonitis (HP) and
to detect HP activity [122]. Indeed, bird-related and house-related HP show seasonal serum KL-6
variations, showing a significant increase in serum KL-6 concentrations in bird-related HP during the
winter and in house-related HP during the summer. Furthermore, serum KL-6 variations have been
reported to be significantly greater in acute HP than chronic HP [123].
Sarcoidosis
In sarcoidosis, serum levels of KL-6 have been reported to vary according to the genotypic distribution of
rs4072037 [124], a single nucleotide polymorphism in exon 2 of the MUC1 gene that has been linked with
MUC1 VNTR size class [125]. In this context, the large molecular size of KL-6/MUC1 has been associated
with the high levels of serum KL-6 reported in sarcoidosis [126, 127]. However, these results are based on
an exceptionally small case–control study subject to type 1 error. Therefore, further research would be
needed to confirm rs4072037 MUC1 genetic linkage with sarcoidosis.
Radiation pneumonitis
Patients lung cancer who have received thoracic radiotherapy (TRT) with or without chemotherapy are at
risk of developing radiation pneumonitis (RP). In this context, serum KL-6 levels have shown a consistent
tendency to increase following clinical diagnosis of severe RP. By contrast, in patients with localised
(within the irradiated field) RP, serum levels do not show a tendency to increase during or after TRT [128].
Drug-induced interstitial pneumonitis
Interstitial pneumonitis can be drug-induced and is characterised by different histological patterns. In the
context of KL-6 serum levels, only diffuse alveolar damage (DAD) and chronic interstitial pneumonia
(CIP) patterns exhibit KL-6 increased serum levels, which are closely correlated with their clinical course.
By contrast, serum KL-6 levels in bronchiolitis obliterans organising pneumonia or eosinophilic
pneumonia (BOOP/EP) patterns are within the normal range [129].
Collagen vascular disease-associated interstitial pneumonia
Collagen diseases are also frequently associated with interstitial pneumonia (IP); the mean serum KL-6
level of patients with both diseases is significantly higher than that of patients with collagen diseases and
inactive IP. Furthermore, serum KL-6 levels have been shown to increase with the deterioration of IP,
while successful treatment of IP results in a significant decrease in KL-6 serum levels [130].
Idiopathic interstitial pneumonias
Idiopathic pulmonary fibrosis (IPF) and patients with nonspecific interstitial pneumonia (NSIP) have also
shown higher BALF KL-6 levels than healthy controls. These levels positively correlate with oxygen
demand at rest and during a 6 min walk test [131], as well as with the extent of fibrotic abnormalities on
HRCT [132].
In the clinic, initial evaluation of serum KL-6 levels has been suggested to predict survival in patients with
IPF [133]. Furthermore, several studies have reported increased serum KL-6 levels during IPF acute
exacerbations, correlating with a rapid decline in forced vital capacity (FVC) predicted and lower survival
rates [134]. Interestingly, MT1-MMP or MMP14 proteins are an alternative mechanism to the MUC1 SEA
self-cleaving domain and shedding to the plasma membrane [135, 136]. Thus, the elevated levels of
MT1-MMP under lung fibrotic conditions [137] are hypothesised to mediate the release of the
extracellular MUC1 domain (MUC1-N/KL-6) in many biological fluids in IPF. Recently, KL-6 serum levels
have been considered a reliable prognostic biomarker indicative of the response to nintedanib treatment in
patients with IPF [138].
There is evidence of weak MUC1/MUC1-CT expression mainly localised to the membrane of ATII cells
and alveolar macrophages in control lung sections [139, 140]. However, under fibrotic conditions, MUC1/
MUC1-CT is overexpressed and located mostly in hyperplastic ATII cells and fibroblasts of fibrotic areas,
being mainly distributed in the cell cytoplasm and nucleus [117, 140] and contributing to IPF pathology.
Furthermore, two phosphorylated/bioactivated forms of MUC1-CT (MUC1-P/T-1224 and MUC1-P/Y-1229)
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have been shown to be overexpressed in IPF lung tissue, with a similar pattern of distribution to that of
nonphosphorylated MUC1-CT [140].
In IPF, MUC1-CT has been reported to collaborate with transforming growth factor (TGF)-β1, promoting
disease progression [140]. Following MUC1-CT phosphorylation/activation via TGF-β1-induced Smad3
phosphorylation, MUC1-CT increases the active form of β-catenin, forming a MUC1-CT/phospho-Smad3/
active-β-catenin nuclear protein complex that promotes fibrotic processes such as the EMT, the fibroblast–
mesenchymal transition (FMT), fibroblast proliferation and ATII and fibroblast senescence [140].
Otherwise, MUC1-CT has also been shown to be activated by galectin 3 [97, 140], whose expression has
been observed to be increased in BALF and serum of patients with stable IPF, as compared with those
with nonspecific interstitial pneumonitis and controls [141]. Furthermore, galectin-3 has been shown to
interact directly with MUC1-C (figure 1), functioning as a bridge between MUC1-C and EGFR, as well as
other cell surface receptors [142]. Indeed, galectin-3 has been reported to promote IPF through
stabilisation of the TGF-β1 receptor (TβR) [141]; it has been hypothesised that galectin-3 might also serve
as a bridge between MUC1-C and TβR, suggesting MUC1-CT might be activated indirectly via p-Smad3
and directly via galectin 3 (figure 5). Importantly, a phase I/II clinical trial (NCT02257177) to assess the
safety, tolerability, pharmacokinetics and pharmacodynamics of TD139, a galectin 3 inhibitor, in patients
with IPF has been successfully conducted.
Additionally, the N-terminal binding of MUC1-N to ICAM-1 has also been related to IPF progression;
ICAM-1 serum levels are elevated in patients with IPF [143] and the MUC1/ICAM-1 association results in
a rapid increase of intracellular calcium in MUC1-expressing cells [144], inducing cytoskeletal changes and
motility.
The effect of MUC1 targeting in the development of pulmonary fibrosis has been studied by using the

































FIGURE 5 The role of MUC1 in IPF. Transforming growth factor β1 (TGF-β1) receptor (TβR) activation induces
Smad3 phosphorylation (1), which phosphorylates MUC1-CT (2). (3) Bioactivated MUC1-CT has demonstrated
to increase the active form of β-catenin, forming a MUC1-CT/phospho-Smad3/active-β-catenin nuclear protein
complex that promotes fibrotic processes such as epithelial to mesenchymal transition, fibroblast to
mesenchymal transition (FMT), fibroblast proliferation and alveolar type II and fibroblast senescence.
(4) MUC1-CT is also activated by galectin 3, which has demonstrated to directly interact with MUC1-C,
functioning as a bridge between MUC1-C and the epidermal growth factor receptor (EGFR), as well as, other
cell surface receptors such as TβR. (5) MUC1-N-terminal binds to intracellular adhesion molecule-1 (ICAM-1)
and the MUC1/ICAM-1 association results in a rapid increase of intracellular calcium in MUC1-expressing
cells, inducing cytoskeletal changes and motility. (6) MUC1-N (KL6) is shed from the cell surface and has
demonstrated to be a diagnosis and prognostic serum biomarker in idiopathic pulmonary fibrosis KL-6: Krebs
von den Lungen-6; LEF: lymphoid enhancer factor; MUC1: mucin 1; SBE: Smad binding element; MUC1-CT:
MUC1 cytoplasmic domain.
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TABLE 1 MUC1 expression and participation in respiratory diseases
Disease MUC1 expression Role of MUC1
Infectious diseases
Pseudomonas aeruginosa Upregulated in lung epithelial cells [35,
36] and alveolar macrophages [39]
During late-stage infection:
Downregulation of TLR5 (epithelial cells)-induced [35, 36] and
TLR4 (macrophages)-induced [39] inflammation
Promotion of neutrophil apoptosis [35, 36]
Haemophilus influenzae Upregulated in airway epithelial cells [27] During late-stage infection:
Downregulation of TLR2-induced inflammation [27]
Respiratory syncytial virus Upregulated in airway epithelial cells
[28, 42]
During last stage infection:
Downregulation of TLR3-induced inflammation [28, 42]
CRSwNP
Corticosteroid responders Upregulated in NP epithelium [54] MUC1-CT/GRα nuclear translocation: anti-inflammatory
effects [5]
Corticosteroid resistant Downregulated in NP epithelium [5] Overactivation of TLR2/5-induced inflammation [5]
GR-Ser226 hyperphosphorylation [5]





Normal expression levels in HBECs and
neutrophils




Downregulation in HBECs and
neutrophils [6]
GR-Ser226 hyperphosphorylation [6]
Reduced formation of the MUC1-CT/GRα nuclear transcription
complex [6]
Impairment of glucocorticoid antinecroptotic effects [67]
Enhancing of viral and bacterial-induced TLR signalling [30]
Paediatric acute
exacerbation [62]
Elevated KL-6 serum levels Biomarker
COPD
Corticosteroid responders Normal expression levels in lung tissue,
bronchial epithelial cells and sputum
neutrophils





Downregulated in lung tissue, bronchial
epithelial cells, and sputum
neutrophils [7]
GR-Ser226 hyperphosphorylation [6]
Reduced formation of the MUC1-CT/GRα nuclear transcription
complex
Acute exacerbation Upregulated MUC1-CT in sputum [75]





Paclitaxel no responders Overexpression and depolarisation in
epithelial cells [77]
Increased CA15-3 serum levels [84, 85]
Inhibition of lung cancer cell apoptosis [92]
Induction of cell proliferation [93]
Induction of EMT [93]
Induction of PD-L1 expression: evasion from immune
recognition [110]
Biomarker
EGFR-TKI no responders Enhanced MUC1-C expression [104] Biomarker for predicting the efficacy of lung cancer treatments
EGFR-TKI partial
responders
High serum KL-6 levels prior to treatment
[106, 107]
Increased serum KL-6 levels after
EGFR-TKI treatment [106]





Elevated KL-6 serum levels [123,
127–132]
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MUC1-C to the nucleus and to attenuate the development of pulmonary fibrosis in a bleomycin-induced
model [140]. Furthermore, antibodies against KL-6 have been shown to attenuate bleomycin-induced lung
fibrosis [145], and MUC1-KO mice have been shown to exhibit resistance to bleomycin-induced
pulmonary fibrosis, with improvements in lung function, survival, and fibrotic lung tissue remodelling
[140]. By contrast, in a silica-induced in vivo model of lung fibrosis, it has been observed that MUC1-KO
mice have increased lung fibrosis [146].
Previously to this paper, higher expression levels of MUC1 in MUC5B+ cells were already registered in the
IPF Cell Atlas (www.ipfcellatlas.com/). MUC5B had been largely reported as a proven lung fibrosis
mediator [147, 148]. Therefore, it further supports the participation of MUC1 in IPF.
In summary, these findings suggest that KL-6 may be a novel, noninvasive marker for the diagnosis and
evaluation of severity in patients with ILD. Furthermore, the detection of activated MUC1-CT in lung
tissue and cells from patients with IPF may be of scientific value in the development of new targets to
treat this devastating disease.
Conclusions
Respiratory diseases include a group of complex diseases with diverse backgrounds. Therefore, diagnosis
and/or treatment are often challenging. As MUC1 is broadly associated with airway defence, airway
inflammation, cell growth, and tissue remodelling processes compatible with the processes observed in
most respiratory diseases (table 1), analysing the expression, distribution, activation and function of MUC1
in lung pathological conditions may be a useful tool for lung disease diagnosis, follow-up and treatment.
However, mucin biology is complex; in spite of numerous pre-clinical and clinical studies focused on
MUC1, further in-depth studies are required before MUC1 can be robustly used as a biomarker for
diagnosis, prognosis or treatment responsiveness or as a new therapeutic approach in lung diseases.
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